Chardan Capital downgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a buy rating to a neutral rating in a report issued on Wednesday, TheFlyOnTheWall.com reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $8.48 in last session, and closed at $8.99, while the day range of stock is $8.22 – $9.05. The stock showed a positive weekly performance of 2.98%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has agreed to sell $20 million of units in a registered direct offering at a price of $1.05 per unit. Each unit consists of one share of common stock and a five year warrant to purchase 0.25 of a share of common stock at an exercise price of $1.28 per share. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $1.19, in last session and closed at $1.35, by gaining 10.66%. The 52 week range of the stock is $0.28 – $1.85. Company’s market capitalization is $63.07 million.
Cell Therapeutics Inc. (NASDAQ:CTIC)’s drug Pixuvri, used for treatment of non-Hodgkin lymphoma, has been deemed “cost-effective” by a health care agency in the United Kingdom. Cell Therapeutics Inc (NASDAQ:CTIC) stock advanced 13.11% and finished the last session at $3.97. The EPS of the stock remained -0.75. Company’s market capitalization is $580.36 million.
BioTelemetry, Inc. (NASDAQ:BEAT) was rising 14.52% to $11.28 on Thursday after the company reported fourth-quarter results that surpassed analysts’ expectations. BioTelemetry, Inc. (NASDAQ:BEAT) stock opened the session at $11.16, and closed the session at $11.19. The 52 week range of the stock remained $2.30 – $11.88 and the day range was $10.82 – $11.67.